<?xml version="1.0" ?>
<document id="dbaaa5a246123fee5013bba144f693f96e624988">
  <chunk id="dbaaa5a246123fee5013bba144f693f96e624988.c0" text="Fidelity Variants of RNA Dependent RNA Polymerases Uncover an Indirect, Mutagenic Activity of Amiloride Compounds">
    <entity charOffset="21-24" id="dbaaa5a246123fee5013bba144f693f96e624988.c0.e0" ontology_id="CHEBI_33697" text="RNA" type="chemical"/>
    <entity charOffset="35-38" id="dbaaa5a246123fee5013bba144f693f96e624988.c0.e1" ontology_id="CHEBI_33697" text="RNA" type="chemical"/>
    <entity charOffset="94-103" id="dbaaa5a246123fee5013bba144f693f96e624988.c0.e2" ontology_id="CHEBI_2639" text="Amiloride" type="chemical"/>
  </chunk>
  <chunk id="dbaaa5a246123fee5013bba144f693f96e624988.c1" text="In a screen for RNA mutagen resistance, we isolated a high fidelity RNA dependent RNA polymerase (RdRp) variant of Coxsackie virus B3 (CVB3). Curiously, this variant A372V is also resistant to amiloride. We hypothesize that amiloride has a previously undescribed mutagenic activity. Indeed, amiloride compounds increase the mutation frequencies of CVB3 and poliovirus and high fidelity variants of both viruses are more resistant to this effect. We hypothesize that this mutagenic activity is mediated through alterations in intracellular ions such as Mg 2+ and Mn 2+ , which in turn increase virus mutation frequency by affecting RdRp fidelity. Furthermore, we show that another amiloride-resistant RdRp variant, S299T, is completely resistant to this mutagenic activity and unaffected by changes in ion concentrations. We show that RdRp variants resist the mutagenic activity of amiloride via two different mechanisms: 1) increased fidelity that generates virus populations presenting lower basal mutation frequencies or 2) resisting changes in divalent cation concentrations that affect polymerase fidelity. Our results uncover a new antiviral approach based on mutagenesis.">
    <entity charOffset="16-19" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e0" ontology_id="CHEBI_33697" text="RNA" type="chemical"/>
    <entity charOffset="20-27" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e1" ontology_id="CHEBI_25435" text="mutagen" type="chemical"/>
    <entity charOffset="68-71" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e2" ontology_id="CHEBI_33697" text="RNA" type="chemical"/>
    <entity charOffset="82-85" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e3" ontology_id="CHEBI_33697" text="RNA" type="chemical"/>
    <entity charOffset="193-202" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e4" ontology_id="CHEBI_2639" text="amiloride" type="chemical"/>
    <entity charOffset="224-233" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e5" ontology_id="CHEBI_2639" text="amiloride" type="chemical"/>
    <entity charOffset="291-300" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e6" ontology_id="CHEBI_2639" text="amiloride" type="chemical"/>
    <entity charOffset="539-543" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e7" ontology_id="CHEBI_24870" text="ions" type="chemical"/>
    <entity charOffset="801-804" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e8" ontology_id="CHEBI_24870" text="ion" type="chemical"/>
    <entity charOffset="881-890" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e9" ontology_id="CHEBI_2639" text="amiloride" type="chemical"/>
    <entity charOffset="1047-1062" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e10" ontology_id="CHEBI_30412" text="divalent cation" type="chemical"/>
    <entity charOffset="1056-1062" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e11" ontology_id="CHEBI_36916" text="cation" type="chemical"/>
    <entity charOffset="1137-1146" id="dbaaa5a246123fee5013bba144f693f96e624988.c1.e12" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
  </chunk>
</document>
